Market Insight - Spinning off assets, AstraZeneca-style
This article was originally published in Scrip
Executive Summary
In the right hands, big pharma's non-core products can be allowed to flourish in newly-formed independent biotech companies. Pete Chan charts one year in the life of AstraZeneca spin-out Albireo.
Every pharmaceutical company under the sun will tell you that it has great scientific assets. But what happens when some of those compounds are deprioritised by a management team's strategic review?
You may also be interested in...
2011 Scrip Asia 100 - Abbott bullish about India but must work hard to retain crown
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
2011 Scrip Asia 100 - Asia life science-focused VC firms
Asia life science-focused VC firms*
2011 Scrip 100: Re-engineering Roche
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.